(AZN) AstraZeneca - Ratings and Ratios
Cancer, Cardiovascular, Respiratory, Rare Diseases, Vaccines
AZN EPS (Earnings per Share)
AZN Revenue
Description: AZN AstraZeneca
AstraZeneca PLC is a leading biopharmaceutical company with a diverse portfolio of prescription medicines across various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and rare diseases. The companys product pipeline is robust, with a range of established brands such as Tagrisso, Imfinzi, and Farxiga, as well as newer additions like Enhertu and Ultomiris.
From a strategic perspective, AstraZeneca has demonstrated a commitment to innovation through partnerships and collaborations, including a notable agreement with Tempus to develop a multimodal foundation model in oncology. Additionally, the companys collaboration with IonQ, Inc. to leverage quantum computing in computational chemistry workflow highlights its willingness to explore cutting-edge technologies. Key Performance Indicators (KPIs) such as Research and Development (R&D) expenditure as a percentage of revenue, and the success rate of its pipeline candidates, will be crucial in assessing the companys long-term growth prospects.
AstraZenecas global presence, with operations in the United Kingdom, the United States, Europe, and Asia, positions it well to capitalize on emerging opportunities in the biopharmaceutical market. The companys ability to serve primary and specialty care physicians through distributors and local representative offices is a key strength. To further evaluate the companys performance, metrics such as revenue growth rate, operating margin, and return on equity (RoE) of 19.18% will be closely monitored.
From a valuation perspective, AstraZenecas Price-to-Earnings (P/E) ratio of 27.89 and Forward P/E of 15.41 suggest a relatively stable valuation. The companys Market Capitalization of $215.9 billion USD underscores its significant presence in the global biopharmaceutical market. To gain a deeper understanding of the companys stock performance, metrics such as dividend yield, beta, and trading volume will be analyzed in conjunction with the provided technical data.
AZN Stock Overview
| Market Cap in USD | 247,430m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1993-05-12 |
AZN Stock Ratings
| Growth Rating | 34.1% |
| Fundamental | 80.2% |
| Dividend Rating | 41.9% |
| Return 12m vs S&P 500 | -20.6% |
| Analyst Rating | 4.42 of 5 |
AZN Dividends
| Dividend Yield 12m | 2.03% |
| Yield on Cost 5y | 3.07% |
| Annual Growth 5y | 1.19% |
| Payout Consistency | 96.4% |
| Payout Ratio | 33.3% |
AZN Growth Ratios
| Growth Correlation 3m | 60% |
| Growth Correlation 12m | 1.1% |
| Growth Correlation 5y | 88.3% |
| CAGR 5y | 9.91% |
| CAGR/Max DD 5y | 0.36 |
| Sharpe Ratio 12m | 0.46 |
| Alpha | -13.57 |
| Beta | 0.235 |
| Volatility | 21.39% |
| Current Volume | 3030.9k |
| Average Volume 20d | 3572.2k |
| Stop Loss | 77.5 (-3.1%) |
| Signal | 0.72 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (8.29b TTM) > 0 and > 6% of Revenue (6% = 3.39b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.14% (prev -6.46%; Δ -1.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 13.39b > Net Income 8.29b (YES >=105%, WARN >=100%) |
| Net Debt (25.78b) to EBITDA (18.57b) ratio: 1.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.12b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 81.40% (prev 82.08%; Δ -0.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.13% (prev 47.09%; Δ 5.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.01 (EBITDA TTM 18.57b / Interest Expense TTM 1.67b) >= 6 (WARN >= 3) |
Altman Z'' 0.81
| (A) -0.04 = (Total Current Assets 28.94b - Total Current Liabilities 33.54b) / Total Assets 112.42b |
| (B) 0.06 = Retained Earnings (Balance) 7.02b / Total Assets 112.42b |
| (C) 0.11 = EBIT TTM 11.74b / Avg Total Assets 108.38b |
| (D) 0.14 = Book Value of Equity 9.48b / Total Liabilities 67.61b |
| Total Rating: 0.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.18
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 3.21% = 1.60 |
| 3. FCF Margin 15.44% = 3.86 |
| 4. Debt/Equity 0.71 = 2.26 |
| 5. Debt/Ebitda 1.70 = 0.58 |
| 6. ROIC - WACC 7.03% = 8.79 |
| 7. RoE 19.84% = 1.65 |
| 8. Rev. Trend 94.91% = 4.75 |
| 9. Rev. CAGR 10.51% = 1.31 |
| 10. EPS Trend 52.04% = 1.30 |
| 11. EPS CAGR 15.72% = 1.57 |
What is the price of AZN shares?
Over the past week, the price has changed by -0.58%, over one month by +12.12%, over three months by +14.43% and over the past year by -6.52%.
Is AstraZeneca a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZN is around 79.75 USD . This means that AZN is currently overvalued and has a potential downside of -0.3%.
Is AZN a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AZN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 86.6 | 8.3% |
| Analysts Target Price | 86.6 | 8.3% |
| ValueRay Target Price | 87.1 | 8.9% |
Last update: 2025-08-27 04:32
AZN Fundamental Data Overview
CCE Cash And Equivalents = 7.11b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 29.9474
P/E Forward = 17.1233
P/S = 4.3792
P/B = 5.523
P/EG = 1.0137
Beta = 0.146
Revenue TTM = 56.50b USD
EBIT TTM = 11.74b USD
EBITDA TTM = 18.57b USD
Long Term Debt = 24.71b USD (from longTermDebt, last quarter)
Short Term Debt = 6.85b USD (from shortTermDebt, last quarter)
Debt = 31.57b USD (Calculated: Short Term 6.85b + Long Term 24.71b)
Net Debt = 25.78b USD (from netDebt column, last quarter)
Enterprise Value = 271.89b USD (247.43b + Debt 31.57b - CCE 7.11b)
Interest Coverage Ratio = 7.01 (Ebit TTM 11.74b / Interest Expense TTM 1.67b)
FCF Yield = 3.21% (FCF TTM 8.72b / Enterprise Value 271.89b)
FCF Margin = 15.44% (FCF TTM 8.72b / Revenue TTM 56.50b)
Net Margin = 14.68% (Net Income TTM 8.29b / Revenue TTM 56.50b)
Gross Margin = 81.40% ((Revenue TTM 56.50b - Cost of Revenue TTM 10.51b) / Revenue TTM)
Tobins Q-Ratio = 28.68 (Enterprise Value 271.89b / Book Value Of Equity 9.48b)
Interest Expense / Debt = 1.39% (Interest Expense 439.0m / Debt 31.57b)
Taxrate = 18.99% (from yearly Income Tax Expense: 1.65b / 8.69b)
NOPAT = 9.51b (EBIT 11.74b * (1 - 18.99%))
Current Ratio = 0.86 (Total Current Assets 28.94b / Total Current Liabilities 33.54b)
Debt / Equity = 0.71 (Debt 31.57b / last Quarter total Stockholder Equity 44.72b)
Debt / EBITDA = 1.70 (Net Debt 25.78b / EBITDA 18.57b)
Debt / FCF = 3.62 (Debt 31.57b / FCF TTM 8.72b)
Total Stockholder Equity = 41.82b (last 4 quarters mean)
RoA = 7.38% (Net Income 8.29b, Total Assets 112.42b )
RoE = 19.84% (Net Income TTM 8.29b / Total Stockholder Equity 41.82b)
RoCE = 17.65% (Ebit 11.74b / (Equity 41.82b + L.T.Debt 24.71b))
RoIC = 13.26% (NOPAT 9.51b / Invested Capital 71.75b)
WACC = 6.23% (E(247.43b)/V(279.00b) * Re(6.88%)) + (D(31.57b)/V(279.00b) * Rd(1.39%) * (1-Tc(0.19)))
Shares Correlation 5-Years: 56.40 | Cagr: 19.15%
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.01% ; FCFE base≈8.02b ; Y1≈9.10b ; Y5≈12.41b
Fair Price DCF = 69.30 (DCF Value 214.85b / Shares Outstanding 3.10b; 5y FCF grow 15.61% → 3.0% )
Revenue Correlation: 94.91 | Revenue CAGR: 10.51%
Rev Growth-of-Growth: 3.21
EPS Correlation: 52.04 | EPS CAGR: 15.72%
EPS Growth-of-Growth: 22.76
Additional Sources for AZN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle